How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2022 financial year.
ESE is funded through a number of industry and non-industry sources:
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- The list of all industry and non-industry revenue sources in 2022 are listed below:
- Ascendis Pharma
- Berlin Chemie
- Bioscientifica
- Clinical Endocrinology Trust
- Consilient Health
- Corcept Therapeutics
- Crinetics Pharmaceuticals Inc.
- Cushing's Support and Research Foundation
- Diurnal Limited
- Eli Lilly
- Hemofarm
- HRA Pharma Rare Diseases
- Inozyme Pharma
- International Medical Press
- Ipsen
- Kyowa kirin
- Malvern Panalytical (for Concept Life Sciences)
- Medinfar
- Merck
- Neurocrine Biosciences
- Novo Nordisk Health Care AG
- Parathyroid UK
- Pfizer Ltd
- Radius Health
- Rare Bone Disease Consortium (COR2ED Agency)
- Recordati AG
- Rhythm Pharmaceuticals
- Savio Pharma
- Simple Pharma
- Soleno Therapeutics
- Springer Healthcare
- Spruce Biosciences
- Swixx Biopharma
- Takeda Pharmaceuticals International AG
- Thyroid Federation International
- Uni Pharma Kleon Tsetis
- Wisepress
- World Alliance of Pituitary Organizations (WAPO)
- Of the revenue into ESE in the 2022 accounts 41.5% was provided by industry.
- The highest contribution from a single company represented 12.9% of the industry revenue and 5.3% of ESE revenue overall.